NewsRoom Articles - Page 4 of 218

WednesdaySep 24, 2025 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

The original FLASH study enrolled 169 patients across three treatment cycles. The ongoing FLASH 2 trial builds on findings found in the first study while addressing regulatory requirements for confirmatory evidence. For Soligenix, the FLASH studies represent more than clinical milestones. These studies are key steps in the company’s regulatory and commercial journey. Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the…

TuesdaySep 23, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

“Screening is the first line of defense,” said IZO CEO Robert Thast, who noted that company’s Breast CT technology can detect cancers as small as two millimeters. Thast summarized Izotropic’s recent advances in artificial intelligence. Company’s commercialization plans start in Europe and then expand to U.S, with focus on selling primarily to hospitals, medical facilities and imaging clinics. A new episode of the BioMedWire Podcast shines a spotlight on Izotropic (CSE: IZO) (OTCQB: IZOZF) and its innovative approach to breast cancer imaging. Featuring IZO CEO Robert Thast, the podcast (ibn.fm/JUWtD) reveals how Izotropic’s proprietary Breast CT technology could transform early…

TuesdaySep 23, 2025 10:00 am

How Federal Policies are Making Health Care More Costly for Families

Most American families are very concerned about health care costs, and recent policy decisions at the federal level will increase the costs that families have to incur for health care. We discuss some of those policy decisions that are causing an uptick in the cost of health care. For starters, the tariffs announced by President Trump and those he is threatening to impose will make the cost of importing prescription drugs into the U.S. higher. As companies incur higher costs to bring in drugs, those additional costs will inevitably be passed on to patients and their caregivers. Given that many…

FridaySep 19, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum

CEO Dr. Vuong Trieu recognized as inventor of multibillion-dollar oncology assets, including Abraxane(R) and Cynviloq(TM) OTLC advancing late-stage pipeline led by OT-101 in Phase 3 for pancreatic cancer and multiple other high-unmet-need indications Recent progress includes 2 years of steady clinical and regulatory advancements across oncology and rare pediatric programs The biotechnology sector is defined by its ability to pair scientific innovation with leadership that can translate discoveries into approved therapies. This is particularly critical in oncology, where late-stage candidates must navigate complex regulatory pathways and demonstrate real clinical impact in indications with limited treatment options. Companies that combine robust…

FridaySep 19, 2025 10:00 am

UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy

A grant of $2 million has been awarded to UCLA Health by a for-profit company, ViewRay Systems. The purpose of this grant is to enable the university to accelerate its research efforts in finding ways in which MRI-guided radiation therapy can be leveraged to provide targeted treatment to cancer patients. Cancer treatments, such as radiation and chemotherapy, are known to impact both diseased and healthy tissues. The impact on healthy tissue causes a variety of side effects, such as hair loss and weight loss, which can affect the health and quality of life of patients. Efforts have therefore been made…

ThursdaySep 18, 2025 10:00 am

New Research Suggests Dietary Change Could Improve Glioblastoma Treatment Outcomes

Researchers at the University of Michigan have published a study which suggests that implementing a dietary adjustment could make glioblastoma, a deadly type of brain cancer, more susceptible to chemotherapy and radiation treatments targeting the tumors in the brain. The study, whose findings appeared in the Nature journal on September 3, suggests that when scientists gain deep understanding of the different mechanisms through which tumor cells alter their metabolic systems inside a patient to boost the proliferation of the tumor, it could unlock novel ways to fight this cancer that has so far been very difficult to treat. Professor Costas…

WednesdaySep 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2 In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed at…

TuesdaySep 16, 2025 10:00 am

New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease

UCLA researchers have developed a smart pen that can detect Parkinson’s during its early stages when the symptoms relied upon for the usual way to diagnose it haven’t shown up yet. Initial tests of this pen revealed an accuracy rate of 96.22%. Currently, Parkinson’s is usually detected when it has advanced so much that it is difficult for existing medications to have any impact in slowing down its progression. This smart pen developed by the UCLA researchers offers an affordable and accessible way to leverage simple acts like writing on a piece of paper to detect the disease long before…

TuesdaySep 16, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease. The therapy improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons. Findings were presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City. CNM-Au8 previously showed positive energetic and metabolic effects in a Phase 2 Parkinson’s trial, aligning with the new preclinical results. The treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in ALS and MS trials. Clene plans to design a Phase 2 clinical study for Parkinson’s…

FridaySep 12, 2025 2:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

Proprietary machine-learning reconstruction algorithm trained on 15 years of breast CT data positions IzoView to redefine global imaging standards Self-supervised approach works on X-ray data before reconstruction, avoiding the delays that cripple competing AI methods Trade secret protection and modality-specific training create durable competitive moats in a crowded, commoditized AI field The medical imaging industry stands at a pivotal juncture. Artificial intelligence promises to revolutionize diagnostics, yet most AI applications in CT imaging remain stuck in theory rather than practice. Conventional AI denoising tools either demand prohibitive computing power, compromise diagnostic clarity, or require impractical training datasets that increase patient…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

How Federal Policies are Making Health Care More Costly for Families

Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum

UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy

New Research Suggests Dietary Change Could Improve Glioblastoma Treatment Outcomes

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search